65,437 trials
Malaria
Primary: Frequency of First Case of Malaria Meeting the Primary Case Definition — 244.77; 238.51; 249.23; 242.06 PYAR — p=<0.001
Type 1 Diabetes
Primary: Count of Participants With no More Than One Meter Glucose Value <50 mg/dL and no Values <40 mg/dL, no More Than Two Episodes With Meter Glucose Values Remaining >300…
Lymphoma, Mantle Cell · Mantle Cell Lymphoma
Primary: Progression Free Survival (PFS) — 27.2; 33.5; 7.8 Months
Infections, Meningococcal
Primary: Anti-Meningitis Antibody Titers by Serum Bactericidal Assay Using Rabbit Complement (rSBA) — 5517.1; 5523.5; 4649.6; 4277.3 Titers
Anesthesia, Local
Primary: Duration of Analgesia — 911; 1026.5; 1181; 982 minutes
Obstructive Sleep Apnea
Primary: Sleep Apnea Severity as Measured by Apnea-hypopnea Index (AHI) — 16.4; 15.8 Events/hour
Peripheral Arterial Disease
Primary: Patients Without Target Lesion Revascularization (TLR) — 186 Participants
Contraception
Primary: Pregnancy — 5.41; 6.67; 6.43 Pearl Index
Measles; Mumps; Rubella · Measles-Mumps-Rubella Vaccine
Primary: Number of Subjects Reporting Fever After MMR (Priorix or M-M-R II/M-M-R VaxPro [Lot 1 or Lot 2]) Vaccination — 47; 17; 205; 95 Participants
Tooth, Nonvital
Primary: Bacterial Levels — 4290; 10800 DNA copies — p=0.04
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 85.1; 70.0; 97.9; 91.7 percentage of participants…
Leukemia
Primary: Overall Response — 11 Participants
Hepatitis B
Primary: Proportion of Participants With Hepatitis B e Antigen (HBeAg) Loss & Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels ≤1,000 International Units (IU) Per…
Complicated Intra-abdominal Infections
Primary: Number of Participants With Clinical Response at the Test of Cure (TOC) Visit — 62; 71 participants
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) After 24 Weeks of Treatment. — -0.38; -1.01 Percentage (%) of HbA1c — p=< 0.0001